TABLE 3.

Longitudinal serologic response data patients with blood sampling captured following each vaccine dose

	Healthy controls	Solid cancers	Hematologic malignancies
Serologic response gained following dose 1	14/15; 93% (70–99)	11/16; 69% (44–86)	1/12; 8% (1–35)
Serologic response gained following dose 2	1/15; 7% (25–70)	4/16; 25% (10–49)	4/12; 33% (14–61)
Serologic response gained following dose 3	—	1/16; 6% (1–28)	1/12; 8% (1–35)
Failed serologic response following three doses	—	—	6/12; 50% (25–75)